Literature DB >> 22873528

The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.

Justin Lowenthal1, Sara Chandros Hull, Steven D Pearson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22873528      PMCID： PMC3469579          DOI： 10.1056/NEJMp1203104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Authors:  Paige E Cramer; John R Cirrito; Daniel W Wesson; C Y Daniel Lee; J Colleen Karlo; Adriana E Zinn; Brad T Casali; Jessica L Restivo; Whitney D Goebel; Michael J James; Kurt R Brunden; Donald A Wilson; Gary E Landreth
Journal:  Science       Date:  2012-02-09       Impact factor: 47.728

2.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

3.  Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe.

Authors:  Jeana Frost; Sally Okun; Timothy Vaughan; James Heywood; Paul Wicks
Journal:  J Med Internet Res       Date:  2011-01-21       Impact factor: 5.428
  3 in total
  8 in total

Review 1.  [Translational research in geriatrics? A plea based on current biomedical key publications].

Authors:  L C Bollheimer; D Volkert; T Bertsch; J Bauer; J Klucken; C C Sieber; R Büttner
Journal:  Z Gerontol Geriatr       Date:  2013-08       Impact factor: 1.281

Review 2.  Microglia: scapegoat, saboteur, or something else?

Authors:  Adriano Aguzzi; Ben A Barres; Mariko L Bennett
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

Review 3.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 4.  Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.

Authors:  Juan M Zolezzi; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

5.  Synthesis of [(11)C]Bexarotene by Cu-Mediated [(11)C]Carbon Dioxide Fixation and Preliminary PET Imaging.

Authors:  Benjamin H Rotstein; Jacob M Hooker; Jiyeon Woo; Thomas Lee Collier; Thomas J Brady; Steven H Liang; Neil Vasdev
Journal:  ACS Med Chem Lett       Date:  2014-02-27       Impact factor: 4.345

Review 6.  Primary Prevention of Dementia: An Ethical Review.

Authors:  Dorothee Horstkötter; Kay Deckers; Sebastian Köhler
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

7.  Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer's Disease.

Authors:  Verónica Vidal; Alba Puente; Susana García-Cerro; María Teresa García Unzueta; Noemí Rueda; Javier Riancho; Carmen Martínez-Cué
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

8.  Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Authors:  Jeffrey L Cummings; Kate Zhong; Jefferson W Kinney; Chelcie Heaney; Joanne Moll-Tudla; Abhinay Joshi; Michael Pontecorvo; Michael Devous; Anne Tang; James Bena
Journal:  Alzheimers Res Ther       Date:  2016-01-29       Impact factor: 6.982
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.